AFFINIA THERAPEUTICS Trademark

Trademark Overview

On Tuesday, January 30, 2024, a trademark application was filed for AFFINIA THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the AFFINIA THERAPEUTICS trademark a serial number of 98383243. The federal status of this trademark filing is RESPONSE AFTER NON-FINAL ACTION - ENTERED as of Friday, June 13, 2025. This trademark is owned by Affinia Therapeutics Inc.. The AFFINIA THERAPEUTICS trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Research and development of pharmaceutical injectables and preparations, namely, vectors and preparations for gene therapy; provision of scientific research information in the field of adeno-associated virus (AAV) vectors and preparations for gene therapy; pharmaceutical engineering services, namely, pharmaceutical products development of vectors and gene therapy pharmaceutical preparations; none of the foregoing in the field of analysis and treatment of tumor associated antigens utilizing immune cells
affinia therapeutics

General Information

Serial Number98383243
Word MarkAFFINIA THERAPEUTICS
Filing DateTuesday, January 30, 2024
Status661 - RESPONSE AFTER NON-FINAL ACTION - ENTERED
Status DateFriday, June 13, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

NOT AVAILABLETHERAPEUTICS
Goods and ServicesResearch and development of pharmaceutical injectables and preparations, namely, vectors and preparations for gene therapy; provision of scientific research information in the field of adeno-associated virus (AAV) vectors and preparations for gene therapy; pharmaceutical engineering services, namely, pharmaceutical products development of vectors and gene therapy pharmaceutical preparations; none of the foregoing in the field of analysis and treatment of tumor associated antigens utilizing immune cells

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, January 30, 2024
Primary Code042
First Use Anywhere DateTuesday, March 31, 2020
First Use In Commerce DateTuesday, March 31, 2020

Trademark Owner History

Party NameAffinia Therapeutics Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWaltham, MA 02453

Trademark Events

Event DateEvent Description
Tuesday, January 30, 2024NEW APPLICATION ENTERED
Thursday, May 30, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, August 23, 2024ASSIGNED TO EXAMINER
Saturday, September 7, 2024NON-FINAL ACTION WRITTEN
Saturday, September 7, 2024NON-FINAL ACTION E-MAILED
Saturday, September 7, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, December 9, 2024APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Monday, December 9, 2024APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Friday, January 24, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, January 24, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, January 24, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, February 6, 2025TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Thursday, February 6, 2025TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, February 6, 2025TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, February 6, 2025ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, February 12, 2025APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, February 12, 2025ASSIGNED TO LIE
Tuesday, March 11, 2025SUSPENSION LETTER WRITTEN
Tuesday, March 11, 2025LETTER OF SUSPENSION E-MAILED
Tuesday, March 11, 2025NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Monday, May 12, 2025TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Wednesday, June 11, 2025SUSPENSION LETTER WRITTEN
Wednesday, June 11, 2025NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Wednesday, June 11, 2025LETTER OF SUSPENSION E-MAILED
Monday, May 12, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, May 12, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, June 11, 2025TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Friday, June 13, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, June 13, 2025TEAS/EMAIL CORRESPONDENCE ENTERED

Related Keywords

therapeutics affinia pharmaceutical preparations gene therapy vectors namely field development research associated